Combination of efavirenz and Truvada [emtricitabine/tenofovir dipivoxil fumarate] (COMET Study): Phase 4 evaluation of switching twice daily Combivir [lamividine/zidovudine] to once-daily regimen co-formulated Truvada in virologically suppressed HIV infected patients taking efavirenz

Trial Profile

Combination of efavirenz and Truvada [emtricitabine/tenofovir dipivoxil fumarate] (COMET Study): Phase 4 evaluation of switching twice daily Combivir [lamividine/zidovudine] to once-daily regimen co-formulated Truvada in virologically suppressed HIV infected patients taking efavirenz

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Dec 2007

At a glance

  • Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary)
  • Indications HIV infections; HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms COMET
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Dec 2007 Status changed from in progress to completed.
    • 26 Jan 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top